11X Stock Market Accelerator Summit

Eric Fry reveals how an A.I.-based secret could make you up to 11 times RICHER on the same stocks you’re investing in now… without using options, leverage, or anything risky.

Wed, September 27 at 8:00PM ET

Is Chamath Palihapitiya Giving Up on Clover Health (CLOV) Stock?


  • Chamath Palihapitiya is selling Clover Health (CLOV), which his SPAC took public.
  • Clover has been losing money due to Covid-19, but should be profitable as the world returns to normal.
  • Palihapitiya has taken as little as $1.55 per share of CLOV stock as he looks for a new adventure.
CLOV stock - Is Chamath Palihapitiya Giving Up on Clover Health (CLOV) Stock?

Source: Dennis Diatel / Shutterstock.com

Clover Health (NASDAQ:CLOV) is losing its sponsor and must fly on alone. Chamath Palihapitiya, the “SPAC King” who brought CLOV stock public in early 2021 at about $16 per share (it’s now at $1.86), has cut his stake in the Medicare Advantage provider to less than 5%. He may have gotten as little as $1.55 per share for some of his stock.

Despite this, Clover was up in pre-market trading on Sept. 30 and continued the trend this morning. Analysts are asking why.

Inside Clover Health

There are excuses for the failures of all Palihapitiya’s special purpose acquisition companies (SPACs). He can still draw headlines, but he’s no longer a billionaire.

I have written about Clover Health in the past with some approval. It offers an app call the Clover Assistant that can help manage chronic conditions like diabetes. The man behind the curtain is Andrew Toy, who officially takes the CEO chair in January.

But all the happy talk disguises poor results. The company has never shown a profit. During the first half of 2022 it lost $180 million, or about 38 cents per share, on revenue of more than $1.7 billion.

Toy blamed Covid-19, which “has shattered actuarial science,” causing far more severe disease and death than could have been predicted. The next year should be more predictable, he says, and that should mean better results.

But can Clover get there? It had only $324 million in cash at the end of June. The fourth quarter is when marketing costs are highest and decisions are made on the next year.

What Happens Next for CLOV Stock?

If Toy is right, Clover Health could have a good 2023. Covid-19 has given insurers pricing power, and costs should be lower as the pandemic becomes endemic.

The best hope for investors is still a sale to a deep-pocketed tech company or major insurer. Toy is a former manager at Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). It would be wrong to speculate, which may be why Palihapitiya is seeking pastures new.

On the date of publication, Dana Blankenhorn held a long position in GOOGL. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Dana Blankenhorn has been a financial and technology journalist since 1978. He is the author of Technology’s Big Bang: Yesterday, Today and Tomorrow with Moore’s Law, available at the Amazon Kindle store. Tweet him at @danablankenhorn, connect with him on Mastodon or subscribe to his Substack.

Article printed from InvestorPlace Media, https://investorplace.com/2022/10/is-chamath-palihapitiya-giving-up-on-clover-health-clov-stock/.

©2023 InvestorPlace Media, LLC